BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

Perspectum raises $36M for digital diagnostics  Perspectum Diagnostics Ltd. raised $36 million in an undisclosed round co-led by Blue Venture Fund and HealthQuest Capital, with participation from Oxford Science Innovation, Puhua Capital, the University of...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

Although Bio-Thera priced its Shanghai IPO Monday, the Guangzhou-based antibody company will likely prove to be the exception among biotechs planning to debut on the Shanghai and Hong Kong exchanges as Asian markets remain volatile...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D  Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
Items per page:
1 - 10 of 15
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

Two years in, the Hong Kong stock exchange’s biotech chapter is no longer an experiment, but a maturing equity market with all the hallmarks to suggest it can sustainably support innovative companies -- as long...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 23, 2020
Finance

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

Perspectum raises $36M for digital diagnostics  Perspectum Diagnostics Ltd. raised $36 million in an undisclosed round co-led by Blue Venture Fund and HealthQuest Capital, with participation from Oxford Science Innovation, Puhua Capital, the University of...
BioCentury | Mar 20, 2020
Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

Although Bio-Thera priced its Shanghai IPO Monday, the Guangzhou-based antibody company will likely prove to be the exception among biotechs planning to debut on the Shanghai and Hong Kong exchanges as Asian markets remain volatile...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D  Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
Items per page:
1 - 10 of 15